Joshua Hayden (Presenter)
Weill Cornell Medical College
Bio: Dr. Hayden is an assistant professor at Weill Cornell Medical College where he serves as the director of the toxicology and therapeutic drug monitoring laboratory and assistant director of the central laboratory. He is a board certified clinical chemist with a special interest in the development and implementation of mass spectrometry assays for therapeutic drug monitoring. Prior to joining the department at Weill Cornell, Dr. Hayden obtained a PhD in chemistry from Carnegie Mellon University and went on to conduct postdoctoral research at the Massachusetts Institute of Technology. He then completed a two year clinical chemistry fellowship at the University of Washington.
Authorship: Chase Adrian Mazur and Joshua Hayden
Weill Cornell Medical College
| Short Abstract The DiaSorin Liaison® chemiluminescent immunoassay (CIA) for total 25-OH vitamin D (25-OH vit D) has begun to replace mass spectrometry as the method of choice in many clinical laboratories. This work examined the performance of this assay in routine clinical practice. A total of 153 paired samples were analyzed by the CIA and an in-house tandem mass spectrometry assay. While the DiaSorin showed acceptable performance overall, substantial negative bias was observed in samples with elevated lipids (total cholesterol, trigycerides and high density lipoprotein (HDL)); mixing studies confirmed the CIA underestimates 25-OH vit D levels in samples with elevated cholesterol. Clinical laboratorians should be aware that the CIA can yield erroneously low 25-OH vit D levels in the presence of elevated lipids. |
Long Abstract
The DiaSorin Liaison® chemiluminescent immunoassay (CIA) for total 25-OH vitamin D (25-OH vit D) has begun to replace mass spectrometry as the method of choice in many clinical laboratories. The current CIA has passed the performance criterion of the Center for Disease Control Vitamin D Standarization program has substantial work has been put into ensuring the accuracy of the results of this assay. This work examined the performance of this assay in routine clinical practice. Over a one-year period, a total of 153 paired samples were analyzed by the CIA and an in-house tandem mass spectrometry assay (used as the gold standard). The DiaSorin showed acceptable performance overall, consistent with published studies. However, substantial negative bias was observed for a small number of samples with some vitamin D replete patients being classified as deficient by the CIA. Chart review showed that these samples all contained high lipid concentrations (total cholesterol, trigycerides and high density lipoprotein (HDL)). Analysis of additional samples at select lipid levels showed that the CIA overestimates 25-OH vit D in the presence of low total cholesterol and underestimates in the presence of high total cholesterol levels. Mixing studies supported the findings that the CIA underestimates 25-OH vit D with increasing total cholesterol. These results have implications for population based studies which have suggested a negative relationship between 25-Oh vit D and lipids. Clinical laboratorians should be aware that the CIA can yield erroneously low 25-OH vit D levels in the presence of elevated lipids.
References & Acknowledgements:
| Description | Y/N | Source |
| Grants | yes | Agilent |
| Salary | no | |
| Board Member | no | |
| Stock | no | |
| Expenses | no |
IP Royalty: no
| Planning to mention or discuss specific products or technology of the company(ies) listed above: | yes |